NEWS UPDATE

ABOUT US

Better Medicine
for a Brighter Tomorrow

‘Sol’ means the Sun and
‘Asia’ the Asian counties in Spanish.
We desire to be the Sun brightening the future of
various people facing many challenges of
cancers in Japan and other Asian countries.

Solasia
at a Glance

View

DEVELOPMENT STATUS

PRODUCTS

PIPELINES INDICATION AREA PRE-
CLINICAL
CLINIAL STUDY NDA APPROVAL
/LAUNCH
PROGRESS PARTNER
PHASE 1 PHASE 2 PHASE 3

Sancuso®(SP-01)

MORE INFO
Chemotherapy Induced Nausea and Vomiting (CINV) China
Launched in 2019

Solasia sales force:

Beijing, Shanghai, Guangzhou

 

Lee’s Pharma:
China Mainland w/o above 3 cities, Hong Kong and Macau


Kyowa Kirin:
[Sublicensee]

Taiwan, Hong Kong etc.
(Launched by Kyowa Kirin)

episil® oral liquid(SP-03)

MORE INFO
Pain associated oral mucositis [Medical Device] Japan
Launched in 2018

Meiji Seika Pharma:

Japan

 

Solasia sales force:

Beijing, Shanghai, Guangzhou

 

Lee’s Pharma:
China Mainland w/o above 3 cities

 

Synex
South Korea

China
Launched in 2019
South Korea
Launched in 2020

PIPELINES

PIPELINES TARGET
INDICATION
AREA PRE-
CLINICAL
CLINIAL STUDY NDA APPROVAL
/LAUNCH
PROGRESS PARTNER
PHASE 1 PHASE 2 PHASE 3

SP-02

MORE INFO
Peripheral T-Cell Lymphoma (PTCL) Japan
Submitted NDA

Meiji Seika Pharma:
Japan


HB Human BioScience:
Latin America

South Korea, Taiwan, Hong Kong
Pivotal PII study completion, preparation for NDA filing
China
Phase II/III, preparation
US
Phase IIA, completion
EU
Pre-clinical, completion

SP-04

MORE INFO
Chemotherapy Induced Peripheral Neuropathy (CIPN) Japan etc.
Pre-clinical study in taxane-induced peripheral neuropathy

Maruho:
Japan

SP-05

MORE INFO
Colorectal Cancer (CRC) Japan
Global Phase III study

CEO Message

View

Corporate
Overview/History

View

PAGE TOP